Introduction {#s1}
============

Deficits in cognition are a hallmark of schizophrenia. The Measurement and Treatment Research to Improve Cognitive in Schizophrenia Initiative (MATRICS) and the CNTRICS group (Cognitive Neuroscience Treatment Research to Improve Cognition in Schizophrenia) seek to further understand the nature of cognitive impairment in schizophrenia and identify new targets for treatment ([@CIT0079]; [@CIT0019]; [@CIT0065]). Both MATRICS and CNTRICS demonstrate the current focus on cognitive impairment associated with schizophrenia and highlight deficits in attention as a core feature of this disorder ([@CIT0078], [@CIT0080]). Attentional impairments are resistant to treatment, precede episodes of psychosis, and may contribute to further, higher-order cognitive impairments ([@CIT0007]; [@CIT0090]). There is, therefore, an important unmet need to understand the neural mechanisms that contribute to attentional impairment in schizophrenia.

Structural and functional brain abnormalities are commonly observed in patients with schizophrenia ([@CIT0071]), including ventricular enlargement ([@CIT0109]), reduced total brain volume ([@CIT0113]), cortical thinning ([@CIT0099]), and decreased grey matter density ([@CIT0047]). While the regional specificity of structural alterations in schizophrenia are heterogeneous ([@CIT0047]), the more consistent morphological alterations include enlargement of the ventricles together with grey matter loss in amygdala, hippocampus, and parahippocampus gyrus ([@CIT0101]). In addition, schizophrenia patients show impaired attentional performance on continuous performance tests and reduced activation of the dorsolateral prefrontal cortex compared with unaffected controls ([@CIT0020]; [@CIT0114]).

Dysfunction of the glutamatergic system, specifically N-methyl-d-aspartate receptor (NMDAR) hypofunction, has been hypothesised to play a central role in schizophrenia pathogenesis ([@CIT0083]; [@CIT0055]). This hypothesis was developed from the observation that NMDAR antagonists (e.g., ketamine and phencyclidine \[PCP\]) could mimic various aspects of disease symptomatology in humans ([@CIT0025]; [@CIT0057]) and exacerbate symptoms in treatment-stabilized schizophrenia patients ([@CIT0059]; [@CIT0066]). In addition, chronic administration of ketamine in humans leads to structural brain abnormalities and reduces functional connectivity ([@CIT0064], [@CIT0062], [@CIT0063]), while acutely administered ketamine impairs regional activation during cognitive and perceptual testing ([@CIT0048]; [@CIT0028]). Collectively, these studies suggest a causal contribution of NMDA-receptor blockade in mediating many of the morphological and functional alterations that underlie the pathophysiology of schizophrenia ([@CIT0037]; [@CIT0032]).

Several behavioral paradigms are commonly used to assess cognitive function in animal models of schizophrenia ([@CIT0116]). One widely-used task is the 5-choice serial reaction time task (5-CSRTT; [@CIT0018]; [@CIT0091]), which was selected by the CNTRICS group as a task with high construct validity in the assessment of attentional impairment in schizophrenia ([@CIT0065]). The 5-CSRTT requires animals to actively detect and respond to brief visuo-spatial stimuli to obtain rewards, thus recruiting elements of sustained and divided attention. In contrast, assessment of sensorimotor gating (prepulse inhibition \[PPI\]) reflects a passive form of attention that enables filtering of irrelevant sensory information ([@CIT0116]). Both dimensions of attention are disrupted in schizophrenia patients, as well as in experimental animals treated with acute PCP ([@CIT0107]; [@CIT0020]; [@CIT0013]; [@CIT0004]).

Previous imaging studies in rats have assessed functional correlates of acutely administered NMDAR antagonists ([@CIT0040]; [@CIT0041], [@CIT0042]; [@CIT0041]; [@CIT0041]; [@CIT0046]). However, repeated drug exposure is thought to more closely model cognitive deficits, negative symptoms, and neuropathological processes relevant to schizophrenia ([@CIT0052]; [@CIT0072]; [@CIT0070], [@CIT0076]). The present study therefore used a well-validated sub-chronic dosing regimen to investigate the effects of PCP on passive (PPI) and active (5-CSRTT) forms of attention in the drug-free state. In addition, e*x-vivo* high-resolution microscopy was carried out with voxel-based morphometry to investigate perturbations in regional brain morphology and cortical thickness in PCP-treated animals.

Methods and Materials {#s2}
=====================

Animals {#s3}
-------

Male hooded-Lister rats (n = 40; Charles River; weighing 350±10g at the start of the experiment) were housed in groups of four on a 12 hour reversed light cycle (lights on at 19:00h) in a temperature-controlled (21±2^o^C) and humidity-controlled (55±5%) environment. Behavioral testing took place during the dark cycle, under red lighting. Animals undergoing behavioral experiments had free access to food (Special Diet Services) and water until one week prior to the beginning of training, where food restriction reduced animal weights to 90% of their free-feeding body weight (approximately 16-18g rat chow/rat/day). Food restriction continued throughout training and testing, with water available *ad libitum* in the home cage. Experiments were conducted in accordance with the UK Animals (Scientific Procedures) 1986 Act and local university ethical guidelines.

Apparatus {#s4}
---------

Twelve 5-hole boxes (25cm x 25cm aluminium chambers), each enclosed within a wooden sound-attenuating cubicle (Med Associates) were used. The rear wall of each testing chamber was concavely curved and contained five response apertures. Each aperture was 2.5cm^2^, 4cm deep, and set 2cm above floor level. Located at the rear of each aperture was a yellow LED providing the visual stimulus. An infrared photocell beam fixed horizontally at the entrance of each aperture registered nose-poke responses. Located on the front wall of the test chamber was a food magazine that allowed retrieval of the food reward (45mg Rodent Pellet, Sandown Scientific). Interruption of an infrared photocell beam at the entrance to the food magazine reported the collection of food rewards and triggered the next trial. A wall-mounted fan provided ventilation and background noise. All twelve chambers were connected to a PC and data was acquired using the Whisker control system v2.5 (Cambridge Cognition; [@CIT0018a])

PPI of the acoustic startle was assessed in startle chambers (Kinder Scientific). Animals were placed in a confinement chamber, beneath which was placed an accelerometer to assess the magnitude of the startle response. Confinement chambers were contained within a sound-attenuating chamber, with startle stimulus and pre-pulse being delivered by a speaker fixed on the sound-attenuating chamber.

Behavioral Procedures {#s5}
---------------------

Rats were trained to detect and report the occurrence of a brief, 1 s visual stimulus presented pseudo-randomly in one of the five available apertures following an inter-trial interval (ITI; 5 s). The procedure was conducted with the house light on, as described previously ([@CIT0010]). Correct detection of the visual stimulus within the limited hold (LH; time period following the stimulus during which animals can make a response, 5 s) was reported via a nose-poke in the illuminated aperture (correct response), resulting in the delivery of food reward. Reward collection initiated the next ITI, during which the animal was required to attend to the array of visual apertures and detect the presentation of the next visual stimulus. A failure to respond to the stimulus (error of omission) or responding to an aperture where the light was not presented (incorrect response) resulted in a 5 s time-out period, whereby the house light was extinguished and no food reward was delivered. A failure to wait for the stimulus presentation---i.e. a nose-poke during the ITI---was recorded as a premature response and initiated a time-out period. Repeat responses in any of the apertures (perseverative response), while recorded, were not punished. The session ended following 100 trials or 30min, whichever occurred first. In previous 5-CSRTT studies, response accuracy and percent correct responding have been used to describe the same measure. These two measures are distinguishable, as accuracy is calculated independently of omissions while percent correct responding is derived from correct, incorrect, and omitted trials. We have used this method of calculating accuracy and percent correct responding, as previously described ([@CIT0006]; [@CIT0011]). Manipulations of basic task parameters are an accepted method of increasing 5-CSRTT difficulty ([@CIT0005]). Sessions that included either a variable stimulus duration (1.0, 0.75, 0.5, 0.25 s) or a variable ITI (8, 6, 4, 2 s) were presented as acute attentional challenges. These were presented in a pseudorandom order with 25 trials for each variable level.

The acoustic startle reactivity paradigm (see [@CIT0039]) began with a 5min acclimation period consisting of 65 dB background white noise. Following acclimation, a series of 6 pulse-alone (40 msec burst of 120 dB noise) trials were presented. This was followed by 25 trials comprising four distinct trial types: pulse alone (described above) and 3 prepulse trials. The prepulse trial included a prepulse stimulus (3, 6, or 12 dB above background for 20ms) that preceded a 120sec pulse trial with an inter-stimulus interval of 100 msec. These four trial types were presented in a pseudorandom order, with 10 pulse-alone trials and 5 of each prepulse trial. The session was concluded by the presentation of 5 consecutive pulse-alone trials. Each trial was interspersed by a variable ITI that averaged 15 s. Percent PPI was calculated as follows: 100-(pp/po) x 100 in which pp = response during prepulse intensity and po = response during pulse only trial.

Behavioral Training {#s6}
-------------------

Rats were habituated to the 5-CSRTT chambers for two days prior to training, and apertures were illuminated and baited to encourage exploration. The training schedule (6 days per week, previously described in [@CIT0010]) started with a stimulus duration (SD) of 120 s. The SD was progressively reduced to the final testing criteria of 1 s. Animals progressed when they reached a stable level of performance \>80% accuracy and \<20% omissions. The LH was also reduced as the animal acquired the task in the same manner as the SD, with the exception that the LH reduction stopped at 5 s, therefore giving testing criteria of 1 s SD and 5 s LH. Throughout the training period, the ITI and time-out period remained at 5 s. Rats were deemed trained when they had reached stable performance at the final protocol (1 s SD, 5 s ITI, 5 s LH) for three consecutive days. The entire training procedure required approximately 12 weeks to complete.

Sub-Chronic PCP Administration {#s7}
------------------------------

PCP was purchased from Sigma-Aldrich. Animals were administered saline (0.9% saline, n = 10) or PCP (5mg/kg, n = 10) via the intra-peritoneal route. The sub-chronic PCP treatment regimen consisted of 7 twice-daily (9 AM and 5 PM) injections followed by a 7-day washout period, previously shown to produce robust, lasting cognitive and social behavioral deficits (reviewed in [@CIT0070], [@CIT0076]). During this 14-day period, animals received no behavioral training or testing. A separate cohort of animals was administered saline (0.9% saline, n = 10) or PCP (5mg/kg intra-peritonealy, n = 10) and perfused after a 15-day washout period to enable *ex-vivo* magnetic resonance imaging to be carried out.

Experimental Design {#s8}
-------------------

A summary of the timeline of experimental procedures is shown in [Figure 1](#F1){ref-type="fig"}. Once trained, all 20 animals were tested on the standard version of the 5-CSRTT (SD 1 s; ITI 5 s) followed by two behavioral challenge sessions. The variable stimulus duration and ITI challenge sessions were interspersed with two baseline (i.e., non-challenge) sessions. Following 5-CSRTT testing, PPI was assessed. After the baseline behavioral testing was completed, the sub-chronic PCP treatment schedule commenced. To determine treatment groups, animals were group-matched based on baseline 5-CSRTT performance as well as task-related performance. Animals were re-tested on the 5-CSRTT, using standard task parameters, 8 days after the last PCP injection. Thereafter, the acute behavioral challenges (variable SD and variable ITI; 10 and 13 days post-PCP) were interspersed with baseline sessions (days 11 and 12) and PPI (14 days post-PCP). A separate cohort of 20 animals was administered PCP or saline in an identical manner and perfused with 4% PFA 15 days post-PCP, prior to high-resolution *ex-vivo* microscopy.

![Experimental timeline. Rats were trained for approximately 3 months on the five-choice serial reaction time task (5-CSRTT). Once trained, behavioral assessment involved standard (SD = 1 s; ITI = 5 s) and challenge (variable SD and ITI) sessions on the 5-CSRTT and PPI. Animals were treated with PCP (n = 10) or saline (n = 10) twice daily for 7 days, followed by a 7-day washout period. After the 1-week treatment regimen, animals were re-assessed in the 5-CSRTT during baseline sessions and challenge sessions, followed by PPI (A). A separate cohort of animals was administered PCP (n = 10) or saline (n = 10) and perfused with 4% PFA to enable *ex-vivo* microscopy to be carried out. Animals were perfused 15-days post-PCP treatment to coincide with the completion of behavioral testing in the first group (B). Values shown are in weeks. BL, baseline 5-CSRTT session; vSD, variable stimulus duration challenge session; vITI, variable inter-trial interval challenge session; PPI, prepulse inhibition; d1 - d7, day 1 - day 7.](ijnppy_pyu010_f0001){#F1}

Magnetic Resonance Imaging {#s9}
--------------------------

Brains were immersed in FluorInert solution (FC-70, 3M) as a susceptibility-matching fluid without any MR signal and scanned at 4.7 T using a Bruker PharmaScan 47/16 system with a 20mm birdcage transmit/receive coil ([@CIT0096]). The pulse sequence used was a rapid acquisition with relaxation enhancement sequence with TR/TE 1500/36ms. Other scan parameters included: field of view (3.1cm × 1.6cm × 1.2cm) with a matrix of 384×200×150 for an isotropic resolution of 80 µm with 8 averages and an echo train length of 10 echoes. Parameters were chosen for optimal contrast between grey and white matter for morphometry.

Voxel Based Morphometry {#s10}
-----------------------

Scans were analyzed using SPM8 following previously established methods ([@CIT0030]). The unified segmentation algorithm of SPM8 with DARTEL was used as modified by SPM Mouse for rat brains ([@CIT0009]; [@CIT0008]; [@CIT0097]). MR images were corrected for radio-frequency coil inhomogeneity and registered to a stereotactic template of the rat brain using SPM8 and SPMMouse ([@CIT0096]). The resulting maps of grey matter were smoothed with a 400 µm Gaussian kernel. Treated and control brains were compared using a two-tailed, two-group student's t-test on a voxel-by-voxel basis. Regions of the brain with a low grey matter score (below 30%) were excluded from the analysis, and areas in the *ex-vivo* data where damage had occurred in extraction were masked before analysis. To control the type I error rate due to multiple comparisons, a voxel-wise height threshold of p \< 0.001 was used, together with an empirically-derived extent threshold of 603 voxels for a corrected family-wise error probability of p \< 0.05.

Cortical Thickness {#s11}
------------------

To specifically investigate alterations in cortical morphology, we used a voxel-based cortical thickness method ([@CIT0050]), as adapted and validated previously for the rodent brain ([@CIT0095]). Briefly, DARTEL registration fields for each subject were used to warp a cortical mask drawn on the template image to the native space of each animal, where cortical thickness values were calculated by integrating streamlines found from Laplace's equation. The resulting maps were then assessed using a general linear model. A two-group student's t-test was used, significant voxels were identified using a height threshold of p \< 0.001, and type I errors were controlled with a family-wise error-adjusted p-value of p \< 0.05, using a cluster extent threshold established with random field theory (SPM). Two-tailed tests were used throughout.

Behavioral Data Analysis {#s12}
------------------------

Behavioral data are displayed as mean ± SEM and analyzed using Statistica v8 (Statsoft). 5-CSRTT data were analyzed by a two-way repeated-measures ANOVA, with day, stimulus duration, ITI, or trial bin (first half of session vs. second half of session) as the repeated measures, where appropriate, and treatment as a fixed factor. To specifically assess post-treatment, between-subject performance, a one-way ANCOVA with treatment as the fixed factor and pre-treatment performance as the covariate was conducted. PPI data were analyzed using a three-way repeated measures ANOVA (with day and treatment the fixed factors and prepulse intensity the repeated measure). Following global analysis of the behavioral data, planned comparisons ([@CIT0103]) were used to assess longitudinal within-subject and/or between-subject effects. For interactions at *p* \< 0.1, we also examined whether lower-order main effects were detectable after subdivision of the interactive variables ([@CIT0102]). The threshold for statistical significance was set at α = 0.05.

Results {#s13}
=======

5-CSRTT: Baseline Session {#s14}
-------------------------

Sub-chronic PCP significantly impaired performance on the standard version of the 5-CSRTT (SD 1 s; ITI 5 s; see [Table 1](#T1){ref-type="table"}). However, these effects were less pronounced compared with those observed during the challenge sessions reported below, and mainly affected the latency of animals to respond correctly (day x treatment interaction, F~(1,18)~ = 6.95, p \< 0.05). Specifically, animals treated with PCP responded more slowly than control rats (p \< 0.05). Apart from significant main effects of day for correct responses (F~(1,18)~ = 6.11, p \< 0.05) and omissions (F~(1,18)~ = 6.17, p \< 0.05), no other significant effects were found.

###### 

).

                         **Pre-treatment**   **Post-treatment**                
  ---------------------- ------------------- -------------------- ------------ -----------------------
  **BL Performance**                                                           
  \% Accuracy            84.5±1.6            83.7±2.3             84.5±1.0     80.3±3.2
  \% Correct             76.4±1.8            77.6±3.4             75.0±1.7     69.7±3.3
  \% Incorrect           14.1±1.3            14.8±2.0             13.7±0.9     17.0±2.8
  \% Omission            9.6±1.7             7.6±2.2              11.3±1.6     13.3±1.5
  \% Premature           8.4±1.8             5.9±1.3              11.2±1.8     9.6±3.3
  Correct Lat (s)        0.72±0.06           0.69±0.04            0.68±0.05    0.76±0.05 \*,^\#^
  Magazine Lat (s)       1.44±0.10           1.40±0.06            1.37±0.09    1.29±0.06
  Perseverative          103.2±9.6           157.8±28.0           131.2±11.4   161.8±26.9
  **vSD Performance**                                                          
  \% Accuracy            75.8±1.4            74.8±2.1             77.4±2.1     67.8±2.2 \*\*, ^\#\#^
  \% Correct             68.3±1.6            66.2±2.3             67.3±2.3     58.2±3.3
  \% Incorrect           21.9±1.4            22.3±1.9             19.9±2.1     27.3±1.7 \*\*, ^\#\#^
  \% Omission            9.8±1.7             11.5±1.6             12.9±2.8     14.5±2.8
  \% Premature           10.2±2.2            6.9±1.4              4.8±1.0      6.3±2.4
  Correct Lat (s)        0.69±0.05           0.71±0.04            0.71±0.05    0.77±0.05
  Magazine Lat (s)       1.36±0.09           1.37±0.04            1.37±0.09    1.36±0.07
  Perseverative          128.0±15.7          167.4±32.5           120.0±12.4   149.5±30.7
  **vITI Performance**                                                         
  \% Accuracy            79.8±2.4            79.8±1.7             80.0±2.0     71.8±3.1 ^\*,\ \#^
  \% Correct             63.4±4.0            58.2±3.2             60.1±3.2     52.0±3.5
  \% Incorrect           15.69±1.7           14.9±1.3             14.7±1.3     19.8±2.0 ^\*,\ \#^
  \% Omission            20.9±3.6            22.1±2.2             25.2±2.6     26.3±3.7
  \% Premature           30.2±4.1            21.7±2.9             24.3±2.8     28.6±2.7
  Correct Lat (s)        0.84±0.03           0.79±0.06            0.84±0.07    0.91±0.05
  Magazine Lat (s)       1.35±0.10           1.35±0.4             1.35±0.85    1.30±0.05
  Perseverative          144.5±13.9          181.0±36.4           130.2±16.6   171.7±35.5

5-CSRTT: Variable Stimulus Duration {#s15}
-----------------------------------

PCP-treated rats were markedly impaired with respect to attentional accuracy (%Accuracy) during the variable stimulus duration challenge session (day x treatment interaction: F~(1,18)~ = 7.79, p \< 0.05). Thus, the attentional accuracy of PCP rats significantly decreased relative to pre-treatment performance and saline control animals (p \< 0.01; [Figure 2A](#F2){ref-type="fig"}). ANCOVA confirmed a significant reduction in response accuracy between control and PCP animals (F~(1,17)~ = 9.85, p \< 0.01). This impairment was driven by a significant increase in incorrect responses (day x treatment interaction, F~(1,18)~ = 8.66, p \< 0.01), revealed by a significant within-subject increase in incorrect responding in PCP-treated animals but not saline-treated animals (p \< 0.01; [Figure 2B](#F2){ref-type="fig"}), and a significant post-treatment group difference between saline and PCP rats (ANCOVA: F~(1,17)~ = 9.66, p \< 0.01). No other significant effects were found during this intervention (see [Table 1](#T1){ref-type="table"}).

![Attentional impairment in rats treated sub-chronically with PCP. Rats were challenged with variable SD (top row) and variable ITI (bottom row) sessions. Response accuracy was reduced in PCP-treated animals in the variable SD session (A). This was mainly attributed to an increase in incorrect responding (B). Analysis of performance, as a function of stimulus duration, revealed a reduction in accuracy of PCP-treated animals when presented with stimuli of 1 and 0.75 s in duration (C). These deficits were restricted to the last half of the session (D). Response accuracy was also reduced in PCP-treated animals when challenged during an acute variable ITI session (E), an effect largely driven by an increase in incorrect responding (F). When performance was analyzed as a function of ITI, a reduction in accuracy was only evident when animals were presented with a 2 s ITI (G). Accuracy impairments were only evident during the second half of the session (H).,Between-subject differences: \*p \< 0.05 and \*\*p \< 0.01. Within-subject differences: \#p \< 0.05 and \#\#p \< 0.01. Open white columns represent saline control animals; open shaded columns represent PCP animals before sub-chronic PCP treatment. Dashed white columns represent saline animals and dashed shaded columns represent PCP treated animals after PCP treatment. Open circles represent saline-treated animals and open-squares denote PCP-treated animals. Data are mean ± SEM.](ijnppy_pyu010_f0002){#F2}

Further analysis demonstrated that response accuracy declined as the stimulus duration decreased (F~(3,54)~ = 12.47, p \< 0.001). ANOVA revealed a main effect of treatment (F~(1,18)~ = 9.22, p \< 0.01) and planned comparisons demonstrated that PCP-treated animals showed significantly reduced attentional accuracy when presented with stimuli of 1 and 0.75sec in duration (p \< 0.05; [Figure 2C](#F2){ref-type="fig"}). Moreover, attentional accuracy declined over the course of the challenge session (trial x treatment interaction, F~(1,18)~ = 5.95, p \< 0.05), with response accuracy significantly reduced in PCP rats compared with controls during the second half of the session (p \< 0.01; [Figure 2D](#F2){ref-type="fig"}). Thus, PCP treatment significantly impaired the ability of animals to maintain accurate performance over the full duration of the session.

5-CSRTT: Variable Inter-Trial Interval {#s16}
--------------------------------------

PCP rats also exhibited impaired attentional accuracy when the inter-trial interval was made unpredictable, a manipulation that taxes sustained attention. Decomposing the near-significant day x treatment interaction (F~(1,17)~ = 4.23, p = 0.055) revealed a within-subject reduction in response accuracy in PCP-treated animals but not saline controls (p \< 0.05), and a significant post-treatment impairment between saline- and PCP-treated animals (F~(1,16)~ = 5.35, p \< 0.05; [Figure 2E](#F2){ref-type="fig"}). Similar to the effects reported above, PCP-treated rats made more incorrect responses than saline-treated animals (day x treatment interaction, F~(1,17)~ = 3.92, p = 0.06), revealed by a significant post-treatment group effect (F~(1,16)~ = 4.75, p \< 0.05; [Figure 2F](#F2){ref-type="fig"}). No other behavioral variable was significantly affected by sub-chronic PCP during this challenge session ([Table 1](#T1){ref-type="table"}).

Attentional accuracy also significantly declined during the variable ITI session (F~(3,54)~ = 8.58, p \< 0.001) and was accompanied by a significant main effect of treatment (F~(1,18)~ = 4.90, p \< 0.05). Based on previous findings ([@CIT0026]), a planned comparison revealed that response accuracy was significantly decreased in PCP-treated rats compared with controls when the ITI was 2 s (p \< 0.05; [Figure 2G](#F2){ref-type="fig"}). Similar to the findings reported for the variable SD session, PCP-treated rats showed a decrement in attentional accuracy during the second half of the session compared with control animals (trial x treatment interaction:, F~(1,15)~ = 8.15, p \< 0.05), demonstrated by significant within- and between-subject effects during the second block of trials (p \< 0.01; [Figure 2H](#F2){ref-type="fig"}).

Prepulse Inhibition {#s17}
-------------------

Analysis of startle magnitude between the two acoustic startle sessions indicated that both saline and PCP rats exhibited habituation to the startle response (F~(1,18)~ = 8.09, p \< 0.05; data not shown). However, although the level of PPI increased predictably as the prepulse intensity increased (F~(2,72)~ = 50.36, p \< 0.001), this was no different between saline and PCP animals ([Figure 3A](#F3){ref-type="fig"} and [B](#F3){ref-type="fig"}).

![Pre-pulse inhibition of the startle response before (A) and after (B) sub-chronic PCP treatment. It can be seen that PCP had no significant effect on prepulse inhibition of the acoustic startle response. A main effect of prepulse effect: \*p \< 0.001. Open white columns represent saline control animals (n = 10); open shaded columns represent PCP animals (n = 10) before sub-chronic PCP treatment. Dashed white columns represent saline control animals; shaded dashed columns represent PCP-treated animals after PCP. Data are mean ± SEM.](ijnppy_pyu010_f0003){#F3}

High-Resolution *Ex-Vivo* Microscopy {#s18}
------------------------------------

The mean cortical thickness of control and PCP rats is shown in [Figure 4](#F4){ref-type="fig"}. Significant clusters demonstrating a reduction in cortical thickness in PCP rats were found in the lateral somatosensory cortex and insula cortex anteriorly and posteriorly bordering the ectorhinal cortex ([Figure 4B](#F4){ref-type="fig"} and [C](#F4){ref-type="fig"}). Qualitatively similar differences were observed bilaterally, though the significance scores were lower on the right side and did not survive correction for multiple comparisons.

![Average voxel-based cortical thickness in rats treated with PCP. Scale bar in mm (A). Areas of significantly reduced cortical thickness in PCP-treated animals compared with saline-treated animals; the scale bar shows student's t-score based on 14 degrees of freedom. Results surviving a cluster-extent correction for family-wise error p \< 0.05 are shown (B). Coronal sections indicating reduced cortical thickness in the insular cortex, left somatosensory cortex (S1; C; panel 1), granular and dysgranular insular cortex (panel 2), granular, dysgranular insular cortex, and ectorhinal cortex (panel 3). Regions identified using [@CIT0085].](ijnppy_pyu010_f0004){#F4}

Significant reductions in grey matter density were observed bilaterally in the anterior cingulate cortex (ACC), ventral striatum (VS), amygdaloid nucleus, and, most prominently, in the hippocampal formation of PCP-treated rats compared with saline-treated rats ([Figure 5](#F5){ref-type="fig"}). No areas of increased grey matter were observed.

![Coronal sections showing areas of significant differences in grey matter between rats treated with saline and PCP. The horizontal scale bar is 2mm; the color scale shows the student's t-score. Results shown are significant at a cluster-level corrected family-wise error of p \< 0.05. The test performed was two-tailed, but only grey matter reductions were observed. ACC, anterior cingulate cortex; VS, ventral striatum; Amyg, amydaloid regions; Hipp, hippocampus.](ijnppy_pyu010_f0005){#F5}

Discussion {#s19}
==========

These findings demonstrate that sub-chronic PCP administration causes a range of structural abnormalities that localize to the hippocampus, ACC, amygdala, insular cortex, and VS. These abnormalities were detected up to 15 days after the last PCP injection and may contribute to impaired attentional function, notably affecting active sustained attention whilst sparing passive attention in terms of sensorimotor gating. Collectively, these findings add specificity to the sequelae of effects produced by protracted NMDAR antagonism whilst also revealing significant overlaps with the spectrum of cognitive and neural abnormalities found in schizophrenia. In particular, our findings implicate NMDAR hypofunction within cortico-amygdalo-hippocampal circuitry, encompassing the VS and ACC as putative key loci underlying attentional dysfunction in schizophrenia.

The present study demonstrates that sub-chronic PCP treatment impairs 5-CSRTT performance in the drug-free state when performance is challenged. During the variable SD challenge session, PCP rats were significantly less accurate than control animals during long SDs. In general, short SDs demand greater attention to facilitate target detection ([@CIT0017]), and this manipulation predictably reduced discriminative accuracy in both control and PCP rats. The deficit when longer (but not shorter) SDs were presented likely represented a floor effect with performance in control animals impaired. However, the increased attentional demands of this manipulation likely exacerbated deficits during the longer SDs, impairing performance in the second half of the session. This deficit could perhaps best be described as a vigilance decrement, as corroborated by recent findings ([@CIT0011]). Consistent with this interpretation, attentional accuracy also declined in PCP rats on trials where the opportunity to respond prematurely was significantly reduced. Deficits following this manipulation were only present when shortest ITI was presented and again emerged during the second half of the session. This variant of the task requires the continuous allocation of finite attentional resources and previously has been shown to reveal a vigilance decrement in rats depleted of acetylcholine in the prefrontal cortex (PFC) ([@CIT0026]). In support of our findings, increasing task difficulty by increasing perceptual load has been shown to temporally degrade continuous attentional performance in schizophrenia patients ([@CIT0077]; [@CIT0068]). Time-on-task deficits have also been reported in schizophrenia patients on related tasks of sustained attention ([@CIT0044]; [@CIT0115]). Our findings thus indicate that sub-chronic PCP produces deficits in sustained attention that resemble a significant component of the attentional impairment present in schizophrenia.

Pre-attentive sensorimotor gating, as assessed by PPI, is also impaired in schizophrenia ([@CIT0013]). However, the neural correlates of PPI are complex, with interactions between sub-cortical and brainstem circuitry being modulated by a number of forebrain structures ([@CIT0035]; [@CIT0013]). Grey matter volume changes in several limbic-striatal structures have been linked to PPI ([@CIT0058]). Our results suggest, however, that while the structural integrity of many of these regions may be vulnerable to disruption by sub-chronic PCP, this alone is not sufficient to impair PPI. Our findings thus replicate previous studies showing PCP to have no effect on PPI in adult rats ([@CIT0067]; [@CIT0031]). However, when administered to neonatal rats, PCP has been shown to impair PPI in adulthood ([@CIT0060]). The mechanism underlying this presumed neurodevelopmental influence is unclear but may involve disruption of GABAergic remodelling during adolescence ([@CIT0081]). Despite GABAergic deficits being evident in rats following both neonatal and adult PCP administration ([@CIT0054]), the absence of PPI deficits in the present study may be attributable to PCP being administered after this critical period of neurodevelopment ([@CIT0087]). Unlike PPI, active attentional processing is less reliant on sensory filtering, and this may explain why sub-chronic antagonism of NMDAR during adulthood selectively impaired sustained, effortful attention.

Our findings show that sub-chronic PCP results in reduced grey matter density in several limbic cortico-striatal structures, including the amygdala, VS, hippocampus, insular cortex, and ACC. Comparable structural abnormalities have been reported in schizophrenia ([@CIT0047]), affecting the amygdala, hippocampus, parahippocampus gyrus, caudate, striatum, and ACC ([@CIT0100]; [@CIT0101]; [@CIT0021]; [@CIT0112]; [@CIT0089]; [@CIT0106]). Cortical thinning in frontal regions ([@CIT0099]) and insular cortexes ([@CIT0088]) are evident. In addition, grey matter deficits in temporal lobe structures, together with structural and functional deficits in the ACC, predict impaired continuous attentional performance in schizophrenia ([@CIT0110]; [@CIT0094]). Moreover, reduced cingulate, caudate, and hippocampus volume is evident in patients with attentional deficits ([@CIT0093]), while decreased amygdala volume has been linked to first-episode psychosis patients ([@CIT0001]). Interestingly, decreased hippocampal and caudate volume has also been reported in relatives of schizophrenia patients ([@CIT0012]) whilst structural deficits that also include the amygdala underlie attentional dysfunction in mania ([@CIT0098]; [@CIT0036]). Along with structural deficits, schizophrenia is associated with functional disconnectivity of several regions, including the ACC, and attentional deficits ([@CIT0049]). Sustained NMDAR hypofunction has recently been shown to compromise functional integration between several brain regions in the rat, with connectivity between frontal and hippocampal structures impaired ([@CIT0027]). These observations encourage the conclusion that the observed structural deficits associated with sub-chronic PCP, localized within discrete regions implicated in schizophrenia pathology and attentional processing, contributed to impaired sustained attention in our study. In addition, our findings implicate NMDAR hypofunction in the spectrum of morphological and attentional deficits found in schizophrenia.

Structural brain abnormalities are widely reported in ketamine abusers ([@CIT0064], [@CIT0062]; [@CIT0111]). Although these structural alterations appear to be less pronounced than those observed in the current study, heterogeneity in terms of age, years of ketamine use, and poly-drug abuse may account for this variance. Nevertheless, the effects of acute ketamine administration and structural deficits associated with chronic NMDAR antagonism suggest similar regional specificity to the regions implicated in the present study. While we cannot rule out PCP-induced neurotoxicity ([@CIT0082]) as a contributing mechanism for the structural deficits we observed, several investigations suggest this may not be the case. High doses of PCP (up to 50mg/kg) produced neurotoxicity in regions including the posterior cingulate/retrosplenial cortex, piriform cortex, olfactory tubercle, and cerebellum ([@CIT0074]; [@CIT0024]; [@CIT0053]). Animals administered 5mg/kg were indistinguishable from saline-treated animals ([@CIT0074]), or alterations indicative of neurotoxicity were transient and restricted to the retrosplenial cortex ([@CIT0024]). Moreover, female rats displayed increased sensitivity to NMDAR neurotoxicity ([@CIT0082]) and were used in several of the studies described above, in contrast to male rats used in the current investigation. Importantly, previous investigations with lower PCP doses (including one using male rats and an identical regimen to ours) did not observe any evidence of PCP-induced neurotoxicity ([@CIT0045]; [@CIT0034]). Given the treatment regimen used and the absence of structural deficits in the posterior cingulate/retrosplenial cortex, piriform cortex, olfactory tubercle, or cerebellum, it is unlikely the structural changes presently described were due to PCP-induced neuronal degeneration or apoptosis. A potential mechanism underpinning our findings may lie with NMDAR antagonists producing excitatory disinhibition via blockade of NMDAR located on GABAergic interneurons ([@CIT0073]). This effect results in increasing activity within limbic cortico-thalamic circuits ([@CIT0072]). Persistent GABAergic impairments are evident following repeated PCP treatments ([@CIT0070]), which are associated with reductions in GAD~67~ and parvalbumin expression ([@CIT0002]; [@CIT0016]; [@CIT0051]). Furthermore, dendritic spine density reductions have also been reported using an identical treatment regimen ([@CIT0045]; [@CIT0033]). Therefore, reductions in both GABAergic markers and dendritic spine density may have contributed to reductions in grey matter and attentional deficits observed in the current investigation.

Sustained attentional performance on the 5-CSRTT depends on the functional integrity of distinct striatal and frontal brain regions coupled with dissociable modulatory influences by the monoamine transmitter systems ([@CIT0091]). Thus, neurotoxic lesions of the ACC in rats selectively impair the accuracy of responding on this task ([@CIT0084]; [@CIT0022]), a deficit that is notably sensitive to modulation at the level of the nucleus accumbens ([@CIT0086]). Moreover, lesions localized to the medial striatum, which together with the nucleus accumbens overlap with the region of reduced grey matter density in the present study, also impair attentional performance on this task ([@CIT0092]). Although initial reports suggested that the hippocampus was not required for 5-CSRTT performance ([@CIT0056]), subsequent investigations in neonatal and adult rats have demonstrated a convincing role of the ventral hippocampus in maintaining performance during increased attentional load ([@CIT0060]; [@CIT0003]). These findings resonate with the profile of PCP-induced structural abnormalities observed in the present study, which likely therefore contributed to the decrement in attentional performance on the 5-CSRTT.

In addition to attentional impairment, sub-chronic PCP administration produces robust impairments in a number of cognitive processes relevant to schizophrenia (for review see [@CIT0070]). For example, PCP disrupts novel object recognition ([@CIT0043]), spatial memory on the Morris water maze ([@CIT0029]), attentional set-shifting ([@CIT0069]), reversal learning ([@CIT0070]), and social behavior ([@CIT0104]). Key neural loci responsible for these impairments include the hippocampus ([@CIT0014]; [@CIT0014]), amgydala ([@CIT0061]), and interactions with the fronto-striatal systems ([@CIT0023]; [@CIT0015]). The spectrum of structural deficits reported in the present study may, as a result, have broader consequences for impaired cognitive processing after sub-chronic exposure to PCP and other NMDAR antagonists.

In summary, our findings reveal a collection of structural and attentional abnormalities associated with sub-chronic PCP administration in rats that may have relevance for schizophrenia. In particular, our results implicate NMDAR dysfunction as a candidate neural mechanism in the emergence of regional volumetric deficits in schizophrenia that may contribute to cognitive deficits in schizophrenia.

Statement of Interest
=====================

Dr Neill has received expenses to attend conferences and fees for lecturing and consultancy work (including attending advisory boards) from the manufacturers of various neuropsychiatric drugs.

This work was supported by Medical Research Council grants to Dr Dalley (G0701500; G0802729) and by a joint core award from the MRC and Wellcome Trust in support of the Behavioural and Clinical Neuroscience Institute at Cambridge University (MRC G1000183; WT 093875/Z/10/Z). This work was completed within the MRC Imperial College-Cambridge University-Manchester University (ICCAM) strategic cluster (G1000018). Dr Jupp was supported by fellowships from the National Health and MRC of Australia and the AXA research fund. Dr Mar has received support from the Innovative Medicines Initiative Joint Undertaking under grant agreement \#115008, whose resources are composed of EFPIA in-kind contributions and financial contribution from the European Union's Seventh Framework Program (FP7/2007--2013). Dr Fletcher has received consultancy fees from GlaxoSmithKline unrelated to this work. Dr Barnes was partly supported by a DTA award to Dr Neill and by b-neuro (b-neuro.com). The authors would like to thank David Theobald for technical assistance and Dr James Kesby for insightful comments during the preparation of the manuscript.
